FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Market Closed - Börse Stuttgart 01:12:25 29/06/2024 am IST | ||
| 8.89 EUR | -0.22% |
|
| Current month | +1.95% | ||
| 1 month | +12.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 8.89 | -0.22% |
| 27/24/27 | 8.91 | +12.22% |
| 26/24/26 | 7.94 | -1.12% |
| 25/24/25 | 8.03 | -5.97% |
| 24/24/24 | 8.54 | +3.89% |
Delayed Quote Börse Stuttgart
Last update June 29, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4CZ7 |
| ISIN | DE000JK4CZ73 |
| Date issued | 22/03/2024 |
| Strike | 171.6 $ |
| Maturity | Unlimited |
| Parity | 6.22 : 1 |
| Emission price | 10.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.21 € |
|---|---|
| Lowest since issue | 5.19 € |
| Spread | 0.3 € |
| Spread % | 3.13% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8
USD
Average target price
283.2
USD
Spread / Average Target
+22.14%
- Stock Market
- Certificates
- Certificat
